CompaniesSelecxine
Selecxine logo

Selecxine

active
Gyeongsangbuk, Korea
Founded 2018
Website
About

Immunotherapeutics

Areas of Focus

Categories

Biologics & BiopharmaceuticalAntibody
Clinical Trials (1)
View all

Total Trials

1

As Lead Sponsor

1

As Collaborator

0

Total Enrollment

420

By Phase

PHASE1/PHASE2: 1

By Status

RECRUITING: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
NCT05525247
Hover over trial bars to see details

Recent Trials

NCT05525247Lead Sponsor
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
PHASE1/PHASE2Recruiting
420 participants
Started: Dec 21, 2022 · Completed: Jan 31, 2028
Locations (1)
Headquarters
Gyeongsangbuk, Korea
Map

Loading map...